Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avai Bio (AVAI) Payables (2018 - 2025)

Avai Bio's Payables history spans 7 years, with the latest figure at $1.2 million for Q1 2024.

  • On a quarterly basis, Payables rose 251.53% to $1.2 million in Q1 2024 year-over-year; TTM through Mar 2024 was $1.2 million, a 251.53% increase, with the full-year FY2024 number at $1.2 million, up 251.53% from a year prior.
  • Payables hit $1.2 million in Q1 2024 for Avai Bio, up from $1.1 million in the prior quarter.
  • Over the last five years, Payables for AVAI hit a ceiling of $1.2 million in Q3 2020 and a floor of $98439.0 in Q2 2020.
  • Historically, Payables has averaged $481160.3 across 5 years, with a median of $321955.5 in 2023.
  • Biggest five-year swings in Payables: skyrocketed 15518.47% in 2020 and later plummeted 59.16% in 2022.
  • Tracing AVAI's Payables over 5 years: stood at $593502.0 in 2020, then fell by 29.25% to $419923.0 in 2021, then tumbled by 38.92% to $256501.0 in 2022, then skyrocketed by 346.59% to $1.1 million in 2023, then grew by 3.08% to $1.2 million in 2024.
  • Business Quant data shows Payables for AVAI at $1.2 million in Q1 2024, $1.1 million in Q4 2023, and $308010.0 in Q3 2023.